ONWARD Schedules Webcast to Provide Third Quarter 2023 Business Update
11 Octubre 2023 - 12:43PM
ONWARD Medical N.V. (Euronext: ONWD), the medical technology
company creating innovative therapies to restore movement,
function, and independence in people with spinal cord injury, today
announced that it will host a webcast to discuss its Q3 2023
business highlights.
The webcast will be held on November 16, 2023, at 2:00PM CET /
08:00AM ET. It will be hosted by CEO Dave Marver and CFO Khaled
Bahi, who will discuss highlights from Q3 2023 and provide a
business update.
To join the webcast via Zoom, please register using this
link.
Participants may also join by phone:
+32 2 290 9360 (Belgium)
+49 69 3807 9884
(Germany)
+31 20 794 0854
(Netherlands)
+41 22 591 0156
(Switzerland)
+44 203 481 5240
(United Kingdom)
+1 346 248 7799 (US)
Additional telephone numbers
available
Meeting ID: 869 3710
5839
A recording of the
webcast will be available on the Company’s website following the
live event.
About ONWARD
Medical
ONWARD is a medical
technology company creating therapies to restore movement,
function, and independence in people with spinal cord injury (SCI)
and movement disabilities. Building on more than a decade of
science and preclinical research conducted at leading neuroscience
laboratories, the Company has received nine Breakthrough Device
Designations from the US Food and Drug Administration for its ARC
Therapy™ platform.
ONWARD® ARC Therapy,
which can be delivered by external ARC-EX™ or implantable ARCIM™
systems, is designed to deliver targeted, programmed spinal cord
stimulation. Positive results were presented in 2023 from the
Company’s pivotal study, called Up-LIFT, evaluating the ability for
transcutaneous ARC Therapy to improve upper extremity strength and
function. The Company is now preparing regulatory approval
submissions for ARC-EX for the US and Europe. In parallel, the
Company is conducting studies with its implantable ARC-IM platform,
which demonstrated positive interim clinical outcomes for improved
blood pressure regulation following 3 SCI. Other ongoing studies
include combination use of ARC-IM with a brain-computer interface
(BCI).
Headquartered in
Eindhoven, the Netherlands, ONWARD has a Science and Engineering
Center in Lausanne, Switzerland and a US office in Boston,
Massachusetts. The Company also has an academic partnership with
.NeuroRestore, a collaboration between the Swiss Federal Institute
of Technology (EPFL), and Lausanne University Hospital
(CHUV).
For more information,
visit ONWD.com, and connect with us on LinkedIn and
YouTube.
For Media
Enquiries:
Aditi Roy, VP
Communications
media@onwd.com
For Investor Enquiries:
Khaled Bahi,
CFO
investors@onwd.com
Disclaimer
Certain statements,
beliefs, and opinions in this press release are forward-looking,
which reflect the Company’s or, as appropriate, the Company
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve several
risks, uncertainties, and assumptions that could cause actual
results or events to differ materially from those expressed or
implied by the forwardlooking statements. These risks,
uncertainties, and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition, and technology, can cause actual events,
performance, or results to differ significantly from any
anticipated development. Forward-looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions, or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release. All ONWARD devices and therapies referenced here,
including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are
investigational and not available for commercial use.
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Onward Medical NV (EU:ONWD)
Gráfica de Acción Histórica
De May 2023 a May 2024